Mariner
CSTL icon

Mariner’s Castle Biosciences CSTL Stock Holding History

Mariner’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$398K Buy
+11,211
New +$338K ﹤0.01% 2615

Other funds holding CSTL

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Jefferies Financial Group
Jefferies Financial Group New York $13.5B AUM 36.68% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $91.6B AUM 30% 1-Year Est. Return

Mariner's CSTL Position: Q3 2026 in Review

Mariner opened a new position in Castle Biosciences (CSTL) in Q3 2026: 11,211 shares worth $398K. The stake represents ﹤0.01% of the portfolio and ranks #2615 among its holdings.

148 funds tracked by Wall St. Rank hold CSTL as of Q3 2026.

  • Mariner held 11,211 shares of Castle Biosciences worth $398K as of Q3 2026.
  • Castle Biosciences was a new Mariner position in Q3 2026.
  • Castle Biosciences made up ﹤0.01% of Mariner's portfolio in Q3 2026, its #2615 holding.
  • 148 funds tracked by Wall St. Rank held Castle Biosciences as of Q3 2026.

Based on Mariner's 13F filing for Q3 2026, filed 12 Nov 2026.